Improved donor chimerism in relapse myelofibrosis post allogenic stem cell transplant with azacitidine and oral decitabine—First case report

To date, allogenic stem cell transplant (ASCT) remains the only potential curative option for patients with primary myelofibrosis (PMF). However, relapse rates and associated mortality remain a concern. A second ASCT may not be feasible due to advancing age, declined functional status, donor unavail...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheung, Verna, Michelis, Fotios V., Sibai, Hassan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9928792/
https://www.ncbi.nlm.nih.gov/pubmed/36819176
http://dx.doi.org/10.1002/jha2.611

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9928792/
https://www.ncbi.nlm.nih.gov/pubmed/36819176
http://dx.doi.org/10.1002/jha2.611

Ejemplares similares